Abstract Arterial hypertension is a major risk factor that can lead to complication of peripheral vascular disease due, in part, to endothelial dysfunction. Because sodium nitrite (SN) can be converted to nitric oxide (NO), which counteracts endothelial dysfunction, we explored the effect of nitrite on neovascularization following hind limb ischemia in different models of hypertension (HT). Chronic delivery of angiotensin II (Ang II, 400 ng/kg/min) or N(omega)-nitro-L-arginine-methyl-ester (L-NAME, 0.1 g/L) was used for a 2-week period to induce hypertension. Mice were subjected to femoral artery ligation-induced ischemia in the hind limb followed by treatment with SN (50 mg/L) for 2 weeks. SN significantly reduced systolic arterial blood pressure in mice receiving Ang II and L-NAME but had no effect in sham animals. After 2 weeks, blood flow and microangiography showed 60 %±1.0 recovery in sham compared with 40 %± 1.3 in HT mice. Importantly, sham and HT mice treated with SN showed a 100 % blood flow recovery associated with normalization in capillary density. The inhibition of xanthine-oxido-reductase (allopurinol) or VEGFR (SU-5416) prevented the neovascularization in HT mice treated with SN. Cyclic GMP (cGMP) content in the hind limb was significantly increased in mice treated with SN compared with non-treated mice. Nitrite/nitrate content was only increased in the sham group treated with SN. Immunoprecipitation and Western blot analysis revealed an increase in eNOS/Akt/VEGFR phosphorylation in skeletal muscle from mice treated with SN compared with non-treated mice. Our findings indicate that SN therapy rescues the neovascularization and blood flow recovery in the ischemic hind limb of sham and HT mice likely through the Akt/NO/cGMP and VEGFR pathways.
Introduction
Arterial hypertension is a major risk factor that can lead to complication of peripheral vascular disease [35] . Previous studies showed that hypertension in human and animal models is associated with endothelial dysfunction and microvascular rarefaction [2] . These data suggest that hypertension contributes to alterations of vascular growth patterns. Therefore, understanding the pathophysiological mechanisms regulating angiogenesis would provide valuable insight into mechanisms of therapeutic angiogenesis for preventing or treating chronic tissue ischemia that occurs in cardiovascular diseases such hypertension.
Nitric oxide (NO) is produced by NO synthase (NOS) in the endothelium and regulates vascular reactivity [29] , which is altered in hypertension [37] . NO is also critical in angiogenesis, as evidenced by the reduction in angiogenesis in mice lacking the gene encoding for endothelial NO synthesis (eNOS) and the enhanced angiogenesis response in animals treated with NO donors [5, 13, 40] . Vascular endothelial growth factor (VEGF) regulates many cellular and molecular events in the neovascularization process such as endothelial cell migration and proliferation [11, 30] . It is well known that shear stress releases NO, which is also an important factor in the mechanism of angiogenesis. Moreover, there are reciprocal interactions between VEGF and NO in the mechanisms of angiogenesis [12, 57] .
Nitrite has previously been used as a marker of NO formation in tissues and plasma [13, 26] . Recently, nitrite was recognized as a beneficial storage form of NO in blood and tissues that initiates rapidly, reduced to NO that initiates cytoprotective signaling in pathological states like kidney ischemia/reperfusion injury [40, 54] . Recent studies described the ability of nitrite to enhance angiogenesis in the ischemic hind limb of normotensive mice [32] . Since our goal is to determine the role of nitrite therapy in impaired angiogenesis related to deficiency of NO associated with hypertension, we chose models of hypertension where the NO pathway is impaired. It has been shown by our group and others that mice infused with angiotensin II or L-NAME display a significant impairment in NO pathway. Therefore, to accomplish our goal, we infused mice with angiotensin II or L-NAME to induce hypertension with impairment in NO pathway and angiogenesis. In these models, we test the hypothesis that sodium nitrite therapy would enhance ischemia-induced angiogenesis.
Methods
Animal model and surgery Sixty male C57BL/6J (8-10 weeks old) were used in the present study. These studies are conformed to the principles of the National Institutes of Health "Guide for the Care and Use of Laboratory Animals," and the Tulane University Institutional Animal Care approved the protocol. Mice were infused with angiotensin II (Ang II) (400 ng/kg/min) [21] or received L-NAME (100 mg/L) for 2 weeks [32] . Then, the hind limb ischemia model was induced in the following groups by ligation of the proximal part of the left femoral artery, as previously described [3, 32, 49] for 2 weeks in: (1) sham, (2) sham + sodium nitrite (50 mg/L in the drinking water) [51] , (3) L-NAME (eNOS inhibitor), (4) L-NAME (in the drinking water) + sodium nitrite ± (allopurinol "xanthine oxidase" or SU-5416 "VEGFR inhibitor" dissolved in DMSO), (5) Ang II (mini-osmotic pump), and (6) Ang II + sodium nitrite ± (allopurinol or SU-5416 ip injection). Hypertension and hind limb ischemia were induced on the same day and lasted for a period of 2 weeks.
Blood pressure Systolic blood pressure (SBP) was measured by tail cuff plethysmography (Softron, BP-98A), before treatment and then once a week as previously described [21] . All mice were trained to the tail cuff measurements 1 week before starting experiments. Measurements were performed at the same time, always at 10 am in the morning, with the same number of measurements (ten trials) for a particular single measurement. The temperature at the time of measurement was the same for all groups of mice. The tail cuff procedure accurately measures SBP but underestimates diastolic blood pressure. Also, changes in time of day, ambient conditions, operator handling of each animal, or subtle behavioral differences between groups, strains, or individual animals can introduce experimental variability to the measurement.
Laser Doppler measurement of hind limb blood flow Hind limb blood flow measurements over the region of interest were performed before surgery, immediately after surgery, and serially over 2 weeks with a MoorLDI-Laser (Moor Instruments). The blood flow of right and left hind limbs was assess by scanning the same lower abdomen and limbs of the mice with a laser Doppler blood flow meter as previously reported [3, 50] .
X-ray quantification of hind limb angiogenesis Vessel density was assessed by high-definition microangiography at the end of the treatment period, as previously described [3, 25] . Briefly, mice were anesthetized, and contrast media (barium sulfate, 1 g/mL) was injected through a catheter introduced into the abdominal aorta. Vessel density quantification was determined using Multi Gauge-Fujifilm.
Immunoprecipitation and Western blot analysis Immunoprecipitation and Western blot analysis were performed as previously described [3, 7, 8, 52] . We used Western blot analysis to assess the phosphorylation and total levels of Akt, eNOS, and VEGFR, in the ischemic and non-ischemic hind limb, using specific antibodies anti-eNOS, anti-Akt, or anti-VEGFR antibodies at the dilution 1:1,000. The quantification of Western blot was determined using FujifilmMulti Gauge software.
Colorimetric determination of nitrite, nitrate, and cGMP Nitrite, nitrate, and cGMP levels were measured in hind limb muscle from all mice. The mice were sacrificed, and the hind limb muscles were immediately harvested and snap frozen in liquid nitrogen. The cGMP measurements were performed using a sandwich enzyme-linked immunosorbent assay (Cayman Chemical, Ann Arbor, MI) according to manufacturer instructions and as previously described [43, 48] . Sham values were considered as 100 %. All data from other groups were normalized to the sham values. For nitrite and nitrate measurements, we used chemiluminescence as previously described [32] .
Immunohistochemistry Immunohistochemistry was performed as previously described [3, 6, 7, 52] . Hind limb tissues were stained with α-actin, von Willebrand factor (Cell Signaling) antibodies, and secondary rabbit antimouse coupled to Alexa Fluor (Molecular Probes). Cellular nuclei were counterstained with DAPI (Molecular Probes). After 2 weeks, mice were anesthetized and perfused with formalin for 45 min. Hind limb muscles were then harvested, sectioned at 5 μm using a cryostat, and then mounted on slides for immunohistochemistry. We used primary antibodies: rabbit polyclonal anti-human factor VIII (DAKO) to detect endothelial cells and mouse monoclonal anti-smooth muscle actin (clone 1A4; Sigma) to detect smooth muscle cells. Goat anti-mouse and chicken antirabbit Alexa-Fluor 594 antibodies were used as secondary antibodies. The capillary density was then determined by counting the number of capillaries in each section of muscle.
Antibodies Phosphorylated VEGF receptor 2 (Tyr951, dilution 1:1,000), total VEGF receptor, total Akt, phosphorylated Akt (Ser476, dilution 1:1,000), total eNOS, phosphorylated eNOS (Ser1177, dilution 1:1,000), von Willebrand factor (dilution 1:1,000), and α-smooth muscle actin (dilution 1:1,000) were purchased from Sigma, Cell Signaling Technology, and Promega.
Statistical analysis Results are expressed as mean ± SEM.
Comparisons between groups in terms of systolic blood pressure, blood flow, vascular density, staining cumulative data, cGMP, nitrite, and nitrate in the tissue and Western blot analysis data were analyzed by using post hoc Bonferroni t tests and Student's t test with a minimum of P< 0.05 to reach significance. Also one-way or two-way ANOVA was used to compare each parameter when there were two independent groups. Values of P <0.05 were considered significant.
Results
Effects of sodium nitrite on systolic blood pressure Systolic blood pressure was increased significantly in mice receiving Ang II infusion or L-NAME treatment compared with sham. Hypertensive mice treated with sodium nitrite (SN) had significantly reduced systolic blood pressure (Fig. 1) . The treatment of sham animal with SN did not alter systolic blood pressure (Fig. 1) .
Effects of sodium nitrite on blood flow recovery in ischemic hind limb from normotensive and hypertensive mice Blood flow was assessed by Doppler flow before, just after surgery, and then once a week for 2 weeks in sham ± SN, L-NAME ± SN, and Ang II ± SN mice (Fig. 2a, b) . After femoral artery ligation, blood flow was significantly reduced to less than 2 % of the value before ligation in all groups associated with a problem in hind limb movement within the first 2 days. After 2 weeks, blood flow was significantly lower in the ischemic hind limb from hypertensive mice compared with sham (Fig. 2) . Interestingly, as shown in Fig. 2b , quantitative analysis of the laser Doppler imaging revealed a significant increase in blood flow recovery in the ischemic hind limb from hypertensive and normotensive mice treated with SN in comparison with non-treated mice.
The inhibition of xanthine-oxido-reductase (allopurinol, 100 mg/kg, ip) or the VEGFR (SU-5416, 50 mg/kg, ip) prevented recovery of flow in the ischemic hind limb of hypertensive mice treated with sodium nitrite (Fig. 2c, d ).
Effects of sodium nitrite on blood vessel density in ischemic hind limb from normotensive and hypertensive mice Vessel density was evaluated by high-definition microangiography at the end of the treatment period. We injected contrast media (barium sulfate, 1 g/ml) into the abdominal aorta, and angiogram from the right and left hind limbs were then examined using digital X-ray (Fig. 3) . After 2 weeks, vessel density in sham mice was significantly lower in the Fig. 1 Effect of sodium nitrite (SN) treatment on blood pressure in normotensive (sham, n010) and hypertensive mice induced by chronic infusion of angiotensin II (Ang II, n010) or L-NAME treatment, n0 10; *P<0.05 for Ang II or L-NAME versus Ang II + SN or L-NAME + SN; # P<0.05 for Ang II and L-NAME versus sham, sham + SN, L-NAME + SN, Ang II + SN; & P<0.05 for L-NAME + SN or Ang II + SN versus sham with and without SN ischemic hind limb compared with the non-ischemic hind limb. However, in sham treated with SN, the ischemic hind limb vessel density was not changed compared with the non-ischemic hind limb. In the group receiving L-NAME or Ang II, vessel density was reduced compared with sham (Fig. 3) . Mice treated with L-NAME or Ang II and then treated with SN displayed a similar pattern vessel density compared with sham mice (Fig. 3) .
Effects of sodium nitrite on capillary density in ischemic hind limb from normotensive and hypertensive mice Blood flow and micro-angiographic data were confirmed by capillary density analysis using von Willebrand factor staining at the end of the treatment period (Fig. 4a, b) . Data showed a significant reduction in von Willebrand factor staining in hypertensive mice which were rescued with SN Fig. 2 Blood flow analysis in the hind limb of hypertensive (angiotensin II "Ang II" or L-NAME) and normotensive mice (sham) treated with or not treated with sodium nitrite (SN); a blood flow measured with MoorLDI-Laser in all groups (sham ± SN, Ang II ± SN, and L-NAME ± SN) before and just after surgery, and once a week for 2 weeks (this image is representative of n010); b alternative strategy for measuring blood flow with MoorLDI-Laser in all groups (sham ± SN, Ang II ± SN, and L-NAME ± SN) before and just after surgery, and once a week for 2 weeks; n010; *P<0.05 for sham + SN, Ang II + SN and L-NAME + SN versus sham; $ P<0.05 statistically significant for sham + SN, Ang II + SN and L-NAME + SN versus Ang II or L-NAME; # P<0.05 for sham + SN, L-NAME + SN, Ang II + SN versus L-NAME or Ang II; c-d blood flow measurements in hypertensive mice treated with sodium nitrite and allopurinol (xanthine-oxido-reductase inhibitor, 100 mg/kg, ip) or SU-5416 (VEGF receptor antagonist, 50 mg/kg, ip) treatment (Fig. 4a, b) . Capillary density was reduced in the ischemic hind limb from hypertensive mice compared with sham (Fig. 4c) . Sham and hypertensive mice treated with SN displayed significant increases in capillary density compared with non-treated mice (Fig. 4c) .
Effects of sodium nitrite on cGMP and nitrite/nitrate content in ischemic hind limb from normotensive and hypertensive mice Colorimetric determination of nitrite, nitrate, and cGMP analysis in hind limb ischemic muscle lysates was performed in all groups. The content of cGMP was decreased in ischemic hind limb from mice receiving L-NAME or Ang II compared with sham. Mice treated with SN showed significantly increased cGMP content in sham and hypertensive mice (Fig. 5a ). The treatment with SN significantly enhanced nitrite and nitrate levels (marker of nitric oxide) in ischemic hind limb from sham, while no effect was observed in mice treated with L-NAME (Fig. 5b) . In mice infused with Ang II, sodium nitrite treatment decreased nitrite and nitrate levels (Fig. 5b) .
Effects of sodium nitrite on Akt, eNOS, and VEGF receptor phosphorylation in ischemic hind limb from normotensive and hypertensive mice Muscle lysates were immunoprecipitated with total antibodies for Akt, eNOS, and VEGF receptor and then blotted with specific antibodies for phosphorylated Akt, eNOS, and VEGF receptor phosphorylation. Akt and eNOS phosphorylation were significantly reduced in hypertensive mice (L-NAME and Ang II) compared with sham, while total Akt and total eNOS were similar in all groups (Fig. 6a, b) . In contrast, sham and hypertensive mice treated with SN displayed an increase in Akt and eNOS phosphorylation Fig. 3 Microangiography determined at the end of the treatment period in all groups (sham ± SN, Ang II ± SN, and L-NAME ± SN). Contrast media (barium sulfate, 1 g/ml) was injected into the abdominal aorta, and then angiogram of the right and left hind limb was assessed with digital X-ray transducer-acquired images. Images were then assembled to obtain a complete view of the hind limb vasculature; image is representative of n05 Fig. 4 a Example of overlapping immunostaining image for von Willebrand factor (green arrow), α-actin (red arrow), DAPI (blue arrow), and overlap between von Willebrand and α-actin (yellow arrow) in mouse hind limb; b amplification of a portion from image in a; c effect of sodium nitrite (SN) treatment on the capillary density in sham and hypertensive mice induced by chronic infusion of angiotensin II (Ang II) or L-NAME. Capillary density was assessed by von Willebrand immunostaining, n05; *P<0.05 for sham versus L-NAME treatment and Ang II; # P<0.05 for sham, L-NAME, and Ang II treated with sodium nitrite versus sham, L-NAME, and Ang II (Fig. 6a, b) . Figure 6c illustrates in sham an increase in VEGF receptor phosphorylation in response to SN while total VEGF receptor expression was similar. VEGF receptor phosphorylation and expression were downregulated in hypertensive animals, and treatment with SN normalized VEGF receptor phosphorylation and expression level (Fig. 6c) .
Discussion
The present study provides evidence supporting the beneficial effect of SN as a therapy to improve neovascularization and eventually blood flow recovery in the ischemic hind limb of normotensive and hypertensive mice. It is well established that NO is an important regulator of vascular homeostasis [14, 23, 24, 46] . Nitric oxide is an autocrine and paracrine signaling molecule with a very short lifetime [15] . Importantly, NO can also be stabilized in blood and tissue by oxidation to nitrate and nitrite and can then be reduced back to NO under physiological and pathological conditions [19] . In most hypertensive animal models, the bioavailability of NO is markedly reduced mainly because of an increase in oxidative stress [9, 35] .
Hypertension was induced by either chronic inhibition of eNOS or infusion of Ang II [18, 20] . The treatment of hypertensive mice with the SN significantly lowered systolic blood pressure, whereas no effect was observed in sham animals. Our data are in agreement with previous results showing that nitrite therapy reduced pulmonary hypertension, and hypertension is induced by L-NAME [27, 34, 58] . These data strongly suggest the beneficial therapeutic role of nitrite in the reduction of hypertension.
Femoral artery ligation was performed in all groups of mice. After 2 weeks, angiogenesis and blood flow recoveries were greater in sham compared with hypertensive mice, indicating an alteration in angiogenesis development. These data are in agreement with previous studies, showing that neovascularization was altered in hypertensive animal models [22, 33, 56] . Angiotensin II has a differential effect on angiogenesis. A non-hypertensive dose was shown to promote angiogenesis [38, 53] , while hypertensive doses of Ang II reduce angiogenesis, as reported in the present and previous studies [36, 56] . These data indicate that the physiological effect of Ang II is to enhance angiogenesis whereas the pathological effect is to reduce angiogenesis. Sham and hypertensive mice treated with SN displayed normalization in hind limb vascularization associated with 100 % blood flow recovery. It was reported that normotensive mice treated with SN had more rapid restoration of blood flow in the ischemic hind limb [32] . These findings are similar to our results, suggesting that continuous nitrite therapy is an effective strategy for enhancing vascularization and eventually tissue perfusion. It has been reported that aldosterone inhibits angiogenesis in response to ischemia [31] . Indeed, in the present study, infusion of Ang II and L-NAME both supports increases in aldosterone levels [42, 47] . The beneficial effect of sodium nitrite therapy could be through the inhibition of aldosterone secretion or through downstream signaling to aldosterone. Future studies are needed to demonstrate the relationship between sodium nitrite and aldosterone in terms of neovascularization in response to ischemia.
To extend our data on the effect of sodium nitrite therapy by its conversion into nitric oxide in our model, mice were treated with allopurinol, an inhibitor of xanthine-oxidoreductase that reduces nitrite to nitric oxide. Allopurinol did not alter systolic blood pressure in L-NAME and Ang II groups treated with sodium nitrite (data not shown). The inhibition of xanthine-oxido-reductase or VEGF receptor prevents neovascularization in hypertensive mice treated with sodium nitrite. These data indicate that the beneficial effect of sodium nitrite, which is to enhance neovascularization in response to ischemia, is mediated by xanthine-oxidoreductase and VEGF receptor. We do not have direct evidence to show reduced nitrite-nitric oxide formation in the tissues, but indirect evidence is supported by the attenuation in ischemia-induced neovascularization in the presence of allopurinol.
The occurrence of vascular rarefaction has been well recognized in hypertensive patients and animal models [4, 44, 45] . Our data suggest that ischemic hind limb from mice treated with L-NAME or Ang II displays a significant reduction in capillary density compared with sham. Sham and hypertensive mice treated with SN show a significant increase in capillary density, indicating that SN is a potent promoter of vascular growth.
It is well established that NO acts through two distinctive signaling pathways, either modulating protein function by S-nitrosation or via binding to the heme of guanylate cyclase, the principal NO receptor. Previous studies show that NO is critical in the process of vascularization [16, 39] . In the present study, we demonstrated that cGMP, the downstream signaling mediator of NO, was reduced in hypertensive mice compared with sham, suggesting that the NO pathway is impaired in hypertension, as previously reported [9, 41] . The sham and hypertensive mice treated with SN had significantly enhanced cGMP levels in the ischemic hind limb. These data are not in agreement with previous studies, showing no change in cGMP levels in mice treated with nitrite [10, 32] . We used another strategy to determine that increased NO was present in the ischemic hind limb of mice treated with SN. We measured nitrite and nitrate content in ischemic hind limb muscle from all mice. These results revealed a significant increase in nitrite and nitrate content in sham mice treated with sodium nitrite. Surprisingly, ischemic hind limb muscle from mice infused with L-NAME did not show an effect while the Ang II group had a high level of nitrite and nitrate content compared with sham and the group of mice treated with L-NAME. In addition, Ang II-induced hypertensive mice treated with SN displayed a reduced level of nitrite and nitrate content compared with Ang II alone. Therefore, it is important to determine in the future whether Ang II and L-NAME could increase nitrite and nitrate content through the induction of iNOS as previously reported [1] .
To emphasize the role of the NO pathway, we measured the phosphorylation of Akt, eNOS, and the VEGF receptor. Western blot analysis and immunoprecipitation studies revealed that Akt, eNOS, and VEGR phosphorylation were significantly reduced in ischemic hind limb from hypertensive mice compared with sham. These data are in agreement with previous studies and suggest that Akt/eNOS/VEGF receptor phosphorylation pathway is impaired in hypertension [28, 55] . Hypertension has a differential effect on Akt/eNOS and VEGR expression. Our data show that Akt and eNOS expression were similar in all groups, while VEGFR expression was significantly reduced in hypertensive mice. Sham and hypertensive mice treated with SN had restored expression and phosphorylation of Akt/eNOS and VEGFR. These results are with agreement in the concept that Akt/eNOS and VEGFR are important factors in angiogenesis [5, 17] .
In this study, we demonstrated that sodium nitrite treatment accelerates angiogenesis and eventually blood flow recovery in the ischemic hind limb from normotensive and hypertensive mice, by modulating the eNOS, Akt, and VEGF receptor pathways. These data provide a new insight in the knowledge of the therapeutic effect of sodium nitrite in the induction of angiogenesis in ischemic tissue, in hypertension.
Clinical perspective
Arterial hypertension is a progressive disease associated with endothelial dysfunction and is a major risk factor for coronary artery disease and subsequent myocardial infarction. Of the patients with peripheral artery disease, 35 to 55 % are hypertensive. It has been shown that chronic sodium nitrite therapy augments ischemia-induced angiogenesis and arteriogenesis in normotensive mice. In the present study, we demonstrated that hypertensive mice treated with sodium nitrite have significantly reduced systolic blood pressure and accelerates angiogenesis and blood flow recovery, probably mediated through VEGF/eNOS/Akt and cGMP pathway. Our data suggest that sodium nitrite could provide novel treatment for arterial hypertension and ischemic diseases by enhancing neovascularization.
